Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

ImmunoMet Therapeutics

  • Benjamin Cowen, ImmunoMet Therapeutics

ImmunoMet is a clinical stage biotech utilizing cellular metabolism to develop novel anti-tumor and immuno-metabolism therapies. ImmunoMet was founded in 2015 as a is Spin-off from HanAll Biopharma, a mid-sized Korean pharma co, and is headquartered at Houston JLABs near MD Anderson. We have raised $20 M post spin-off including $10 M from VCs. Our lead molecule, IM156, is an OXPHOS inhibitor which has demonstrated impressive in vivo efficacy in resistant solid tumors and entered Phase 1 in 4Q17. ImmunoMet owns a large biguanide library which forms an engine we are leveraging to unlock value and develop products in immuno-metabolism.

  • Date:Tuesday, February 12
  • Time:1:30 PM - 1:45 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23263
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Seeking new investors
  • Company Website:http://www.immunomet.com
  • Company HQ City:Houston
  • Company HQ State:Texas
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$19M
  • Year Founded:2015
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:IM156
  • Development Phase of Primary Product:Phase I
Speakers
Benjamin Cowen
ImmunoMet Therapeutics
Back